Article

Ponatinib Provides Higher Rate of MRD-negative CR Vs Imatinib in Newly Diagnosed Ph+ ALL

Author(s):

Ponatinib plus reduced-intensity chemotherapy produced a higher rate of minimal residual disease–negative complete remission compared with imatinib in patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.

Awny Farajallah, MD

Awny Farajallah, MD

Ponatinib (Iclusig) plus reduced-intensity chemotherapy produced a higher rate of minimal residual disease (MRD)–negative complete remission compared with imatinib (Gleevec) in patients with newly diagnosed Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL), meeting the primary end point of the phase 3 PhALLCON trial (NCT03589326).1

No new safety signals with the combination were observed, according to the press release issued by Takeda.

“Ph-positive ALL is a fast-progressing disease with no targeted treatments currently approved in the frontline for patients in the United States. There is an urgent need for an effective treatment that can suppress the development of difficult-to-treat mutations, which are associated with poor long-term outcomes,” Awny Farajallah, MD, head of Global Medical Affairs Oncology at Takeda, stated in the press release. “We are excited to see how [ponatinib] may be able to address this gap in care for these patients and look forward to sharing the results.”

The open-label, parallel-assignment, randomized trial enrolled patients with newly diagnosed Ph-positive or BCR::ABL1–positive ALL who were at least 18 years of age and who had an ECOG performance status of 0 to 2.2,3

Exclusion criteria include having a history or current diagnosis of chronic phase, accelerated phase, or blast phase chronic myeloid leukemia; prior or current treatment with any systemic anticancer therapy and/or radiotherapy for ALL; uncontrolled active serious infection that could interfere with treatment; major surgery within 28 days prior to randomization; and a history of acute pancreatitis within 1 year of screening; among others.

Study participants were randomly assigned 2:1 to receive ponatinib at a daily dose of 30 mg or imatinib at a daily dose of 600 mg paired with reduced-intensity chemotherapy in induction phase (cycles 1 to 3), consolidation phase (cycles 4 to 9), and maintenance phase (cycles 10 to 20). At the end of the 20 cycles, participants will remain on either TKI.

Treatment will continue until relapse from CR, disease progression, intolerable toxicity, withdrawn consent, patients proceed to hematopoietic stem cell transplant, the study is completed, death, or the study is terminated by the sponsor.

The primary end point of the trial is MRD-negative CR at the end of the indication phase of treatment, which was approximately 3 months. Secondary end points include event-free survival, CR/incomplete blood count recovery rates, molecular response rates, MRD-negative CR duration, primary induction failure, overall response rate, CR duration, time to treatment failure, overall survival, and safety.

In January 2019, the first patient underwent randomization. Approximately 226 patients were randomized as of February 2022.

Additional findings from the trial will be shared with regulatory authorities and with the scientific community in the future.

References

  1. Phase 3 trial of ICLUSIG (ponatinib) met primary endpoint in newly-diagnosed Ph+ ALL, a setting with no targeted treatments approved in the US. News release. Takeda. November 17, 2022. Accessed November 17, 2022. http://bit.ly/3GmGjyg
  2. A study of ponatinib versus imatinib in adults with acute lymphoblastic leukemia. ClinicalTrials.gov. Updated November 10, 2022. Accessed November 17, 2022. https://clinicaltrials.gov/ct2/show/NCT03589326
  3. Jabbour E, Martinelli G, Vignetti M, et al. PB1762: ponatinib versus imatinib with reduced-intensity chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acue lymphoblastic leukemia (ALL): PhALLCON study. Hemasphere. 2022;6:1643-1644. doi:10.1097/01.HS9.0000849904.09812.c6
Related Videos
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)
Hannah Choe, MD, an expert on GVHD
Hannah Choe, MD, an expert on GVHD
Indirect Comparison of Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
Hua-Jay “Jeff” Cherng, MD, assistant professor, medicine, Lymphoma Program, Division of Hematology and Oncology, Columbia University Irving Medical Center
Naval G. Daver, MD
DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM)
Joseph Maakaron, MD, assistant professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Marie Hu, MD, assistant professor, medicine, Division of Hematology, Oncology and Transplantation, the University of Minnesota Medical School